Angiotensin-neprilysin inhibition versus enalapril in heart failure
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS: The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“showed superior efficacy of ARNI therapy over enalapril in chronic HF patients already receiving maximally tolerated dose of a renin-angiotensin system inhibitor (RASi).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [5]
In the citing paper
“Neprilysin inhibition does not seem to add to this effect.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“Neprilysin inhibition needs to be studied further, but does not seem to enhance this effect.224”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [224]
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [31]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
(1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,929
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationA Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Cited by
Items 201–300 of 1,026
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure
Fu, S., Ping, P., Wang, F., & Luo, L. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-017-0093-0 · Cited by 198
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
Docherty, K. F., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., Bengtsson, O., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa183 · Cited by 198
“The first was the sinus node inhibitor, ivabradine, followed by the neprilysin inhibitor sacubitril and most recently, the SGLT2 inhibitor, dapagliflozin.(2,16,17) In the present report, we have shown that dapagliflozin not only improves outcomes when added to the core combination of RAS blocker, BB and MRA but also h…”
BackgroundSelf-citationConrad, N., Judge, A., Canoy, D., Tran, J., Pinho-Gomes, A.-C., Millett, E. R. C., Salimi-Khorshidi, G., Cleland, J. G., McMurray, J. J. V., & Rahimi, K. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3593 · Cited by 197
Self-citationDoehner, W., Ural, D., Haeusler, K. G., Čelutkienė, J., Bestetti, R., Cavusoglu, Y., Peña-Duque, M. A., Glavas, D., Iacoviello, M., Laufs, U., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1100 · Cited by 198
Sun, L. Y., Gaudino, M., Chen, R. J., Bader Eddeen, A., & Ruel, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0239 · Cited by 195
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
“Clinical trials of the ARB—neprilysin inhibitor (ARNI) combination of valsartan and sacubitril, have demonstrated significant efficacy in reducing symptoms, hospitalization and mortality in HFrEF in addition to standard therapy, including RAAS inhibition (McMurray et al, 2014).”
BackgroundBrisco, M. A., Zile, M. R., Hanberg, J. S., Wilson, F. P., Parikh, C. R., Coca, S. G., Tang, W. H. W., & Testani, J. M. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.06.423 · Cited by 196
Self-citationHeart failure in patients with kidney disease
Tuegel, C., & Bansal, N. (2017) · Heart · doi:10.1136/heartjnl-2016-310794 · Cited by 195
Hypertrophic Cardiomyopathy: The Future of Treatment
Tuohy, C. V., Kaul, S., Song, H. K., Nazer, B., & Heitner, S. B. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1715 · Cited by 194
Sliwa, K., Petrie, M. C., van der Meer, P., Mebazaa, A., Hilfiker-Kleiner, D., Jackson, A. M., Maggioni, A. P., Laroche, C., Regitz-Zagrosek, V., Schaufelberger, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa455 · Cited by 196
Self-citationSex- and Gender-Based Pharmacological Response to Drugs
Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J.-J., Dhakal, S., Franconi, F., Gouni-Berthold, I., Heiman, M. L., Kautzky-Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 192
“ABBREVIATIONS: ACE, angiotensin-converting enzyme; ACEI, ACE inhibitor; ADR, adverse drug reaction; AhR, aryl hydrocarbon receptor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CIBIS II, Cardiac Insufficiency Bisoprolol Study II; CVOT, cardiovascular outcome trial; DPD, dihydropyrimidine dehydrogen…”
BackgroundInfluentialAtrial natriuretic peptide in cardiovascular biology and disease (NPPA)
Song, W., Wang, H., & Wu, Q. (2015) · Gene · doi:10.1016/j.gene.2015.06.029 · Cited by 193
“In recent clinical trials, a small molecule compound inhibiting the angiotensin II receptor type 1 and NEP, which degrades the natriuretic peptides, exhibited therapeutic benefits in HF patients (McMurray et al., 2014).”
BackgroundRole of endothelial dysfunction in heart failure
Zuchi, C., Tritto, I., Carluccio, E., Mattei, C., Cattadori, G., & Ambrosio, G. (2020) · Heart Failure Reviews · doi:10.1007/s10741-019-09881-3 · Cited by 191
“the PARADIGM-HF trial administration sacubitril/valsartan, a molecule combining a neprilysin inhibitor that inhibits NP degradation with an angiotensin II receptor blocker, which resulted in a significant reduction in cardiovascular death and hospitalizations for HF in patients with HFrEF compared with enalapril [98]…”
BackgroundHarkness, A., Ring, L., Augustine, D. X., Oxborough, D., Robinson, S., & Sharma, V. (2020) · Echo Research & Practice · doi:10.1530/erp-19-0050 · Cited by 191
Abnormalities of Potassium in Heart Failure
Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 190
Meijers, W. C., Bayes‐Genis, A., Mebazaa, A., Bauersachs, J., Cleland, J. G. F., Coats, A. J. S., Januzzi, J. L., Maisel, A. S., McDonald, K., Mueller, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2346 · Cited by 186
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 183
Voors, A. A., Gori, M., Liu, L. C. Y., Claggett, B., Zile, M. R., Pieske, B., McMurray, J. J. V., Packer, M., Shi, V., Lefkowitz, M. P., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.232 · Cited by 187
“002).(3) These findings corroborate our results suggesting that LCZ696 may have direct renal effects on top of the effects of RAAS blockade, such as valsartan, alone.”
ResultSelf-citationOkumura, N., Jhund, P. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Swedberg, K., Zile, M. R., Solomon, S. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020729 · Cited by 186
Self-citationUpdates on Acute Coronary Syndrome: A Review
Eisen, A., Giugliano, R. P., & Braunwald, E. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2049 · Cited by 185
de Diego, C., González-Torres, L., Núñez, J. M., Centurión Inda, R., Martin-Langerwerf, D. A., Sangio, A. D., Chochowski, P., Casasnovas, P., Blazquéz, J. C., & Almendral, J. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2017.11.012 · Cited by 183
Frantz, S., Falcao-Pires, I., Balligand, J.-L., Bauersachs, J., Brutsaert, D., Ciccarelli, M., Dawson, D., de Windt, L. J., Giacca, M., Hamdani, N., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1138 · Cited by 184
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Self-citationThe neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
Jhund, P. S., & McMurray, J. J. V. (2016) · Heart · doi:10.1136/heartjnl-2014-306775 · Cited by 181
Self-citationSGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013389 · Cited by 183
“converting-enzyme inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial showed benefit with ARNI, valsartan/sacubitril.(30) Consequently, both European(5) and US(6) guidelines make the strongest recommendation for use of these neurohormonal agents, up-titrated to optimal doses shown…”
BackgroundCombined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
Vardeny, O., Miller, R., & Solomon, S. D. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2014.09.001 · Cited by 181
Self-citationMartens, P., Beliën, H., Dupont, M., Vandervoort, P., & Mullens, W. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12435 · Cited by 179
Mc Causland, F. R., Lefkowitz, M. P., Claggett, B., Anavekar, N. S., Senni, M., Gori, M., Jhund, P. S., McGrath, M. M., Packer, M., Shi, V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047643 · Cited by 179
Self-citationViral Myocarditis—Incidence, Diagnosis and Management
Olejniczak, M., Schwartz, M., Webber, E., Shaffer, A., & Perry, T. E. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.12.052 · Cited by 180
Utility of patient-reported outcome instruments in heart failure
Kelkar, A. A., Spertus, J., Pang, P., Pierson, R. F., Cody, R. J., Pina, I. L., Hernandez, A., & Butler, J. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.10.015 · Cited by 179
“Food and Drug Administration has helped propel the use of PRO in the clinical trials (18).”
BackgroundSex Differences in Heart Failure
Lala, A., TAYAL, U., HAMO, C. E., YOUMANS, Q., AL-KHATIB, S. M., BOZKURT, B., DAVIS, M. B., JANUZZI, J., MENTZ, R., SAUER, A., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.10.006 · Cited by 179
Ezekowitz, J. A., Colin-Ramirez, E., Ross, H., Escobedo, J., Macdonald, P., Troughton, R., Saldarriaga, C., Alemayehu, W., McAlister, F. A., Arcand, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00369-5 · Cited by 179
G Protein-Coupled Receptors: A Century of Research and Discovery
Liu, S., Anderson, P. J., Rajagopal, S., Lefkowitz, R. J., & Rockman, H. A. (2024) · Circulation Research · doi:10.1161/circresaha.124.323067 · Cited by 176
“152 Although ACEIs and ARBs are currently mainstays in the treatment of hypertension and HF, AT 1 R β -arrestin biased agonists have a theoretical advantage over ARBs that block both G-proteins and β -arrestins.”
Spitzer, E., Van Mieghem, N. M., Pibarot, P., Hahn, R. T., Kodali, S., Maurer, M. S., Nazif, T. M., Rodés-Cabau, J., Paradis, J.-M., Kappetein, A.-P., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.08.009 · Cited by 177
Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2021.4567 · Cited by 178
Medical Therapy for Heart Failure Caused by Ischemic Heart Disease
Elgendy, I. Y., Mahtta, D., & Pepine, C. J. (2019) · Circulation Research · doi:10.1161/circresaha.118.313568 · Cited by 176
Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047077 · Cited by 175
Self-citationVardeny, O., Claggett, B., Kachadourian, J., Desai, A. S., Packer, M., Rouleau, J., Zile, M. R., Swedberg, K., Lefkowitz, M., Shi, V., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1402 · Cited by 174
Self-citationThe renin-angiotensin-aldosterone system and its therapeutic targets
Mirabito Colafella, K. M., Bovée, D. M., & Danser, A. H. J. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.05.020 · Cited by 175
Therapeutic targets for cardiac fibrosis: from old school to next-gen
Travers, J. G., Tharp, C. A., Rubino, M., & McKinsey, T. A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148554 · Cited by 173
“Clinically, ARB and NI treatment reduces circulating biomarkers of cardiac fibrosis (73), and was shown to improve outcomes in human patients compared with treatment with ACEIs (74), leading to the FDA approval of sacubitril/valsartan.”
BackgroundSex and Gender Differences in Heart Failure
Regitz-Zagrosek, V. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2020.0004 · Cited by 174
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 171
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 171
Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events
Kerkelä, R., Ulvila, J., & Magga, J. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002423 · Cited by 170
“Combined angiotensin receptor blockade and neprilysin inhibition by LCZ696 significantly reduced the risk of hospitalization for HF and the number of deaths for cardiovascular causes.(117) Importantly, no major safety concerns of the combination emerged during the study.”
BackgroundTargeting amyloid clearance in Alzheimer's disease as a therapeutic strategy
Nalivaeva, N. N., & Turner, A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14593 · Cited by 172
Savarese, G., Bodegard, J., Norhammar, A., Sartipy, P., Thuresson, M., Cowie, M. R., Fonarow, G. C., Vaduganathan, M., & Coats, A. J. S. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2271 · Cited by 171
Modin, D., Jørgensen, M. E., Gislason, G., Jensen, J. S., Køber, L., Claggett, B., Hegde, S. M., Solomon, S. D., Torp-Pedersen, C., & Biering-Sørensen, T. (2019) · Circulation · doi:10.1161/circulationaha.118.036788 · Cited by 170
Self-citationD'Elia, E., Iacovoni, A., Vaduganathan, M., Lorini, F. L., Perlini, S., & Senni, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.799 · Cited by 169
Bhagat, A. A., Greene, S. J., Vaduganathan, M., Fonarow, G. C., & Butler, J. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.06.011 · Cited by 169
“Although the PARADIGM-HF (Prospective Comparison of ARNI With an ACEInhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial showed that sacubitril/valsartan was superior to enalapril in reducing cardiovascular events in stable patients with HFrEF, limited data are available regarding th…”
MethodMorrow, D. A., Velazquez, E. J., DeVore, A. D., Desai, A. S., Duffy, C. I., Ambrosy, A. P., Gurmu, Y., McCague, K., Rocha, R., & Braunwald, E. (2019) · Circulation · doi:10.1161/circulationaha.118.039331 · Cited by 170
Self-citationvan Gils, L., Clavel, M.-A., Vollema, E. M., Hahn, R. T., Spitzer, E., Delgado, V., Nazif, T., De Jaegere, P. P., Geleijnse, M. L., Ben-Yehuda, O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.023 · Cited by 167
“AS gradually progresses, with an annual reduction in aortic valve area Peripheral arterial disease 60 (20) Prior stroke 43 (14) NYHA functional class I 79 (26) II 129 (42) III 86 (28) IV 12 (4) Index echocardiography LVEF, % 38 9 AVA, cm(2) 1.”
InfluentialThe New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications
Lytvyn, Y., Bjornstad, P., van Raalte, D. H., Heerspink, H. L., & Cherney, D. Z. I. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz010 · Cited by 165
Current and future treatments of pulmonary arterial hypertension
Sommer, N., Ghofrani, H. A., Pak, O., Bonnet, S., Provencher, S., Sitbon, O., Rosenkranz, S., Hoeper, M. M., & Kiely, D. G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15016 · Cited by 166
“Recently, a combination of the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril was approved for treatment of left heart failure (McMurray et al., 2014).”
Background3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure
Mack, M. J., Lindenfeld, J., Abraham, W. T., Kar, S., Lim, D. S., Mishell, J. M., Whisenant, B. K., Grayburn, P. A., Rinaldi, M. J., Kapadia, S. R., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.047 · Cited by 165
Medical Treatment of Aortic Stenosis
Marquis-Gravel, G., Redfors, B., Leon, M. B., & Généreux, P. (2016) · Circulation · doi:10.1161/circulationaha.116.023997 · Cited by 162
Butler, J., Hamo, C. E., Filippatos, G., Pocock, S. J., Bernstein, R. A., Brueckmann, M., Cheung, A. K., George, J. T., Green, J. B., Januzzi, J. L., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.933 · Cited by 164
Pieske, B., Wachter, R., Shah, S. J., Baldridge, A., Szeczoedy, P., Ibram, G., Shi, V., Zhao, Z., Cowie, M. R., PARALLAX Investigators and Committee members, et al. (2021) · JAMA · doi:10.1001/jama.2021.18463 · Cited by 163
Self-citationGlobal Left Atrial Failure in Heart Failure
Triposkiadis, F., Pieske, B., Butler, J., Parissis, J., Giamouzis, G., Skoularigis, J., Brutsaert, D., & Boudoulas, H. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.645 · Cited by 160
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 161
Inflammation in heart failure: pathophysiology and therapeutic strategies
Boulet, J., Sridhar, V. S., Bouabdallaoui, N., Tardif, J., & White, M. (2024) · Inflammation Research · doi:10.1007/s00011-023-01845-6 · Cited by 200
“While Gal-3 was elevated at base-line in PARADIGM-HF, there was no statistically significant difference between treatment groups with respect to changes in Gal-3 [86].”
BackgroundHeart Failure With Preserved Ejection Fraction
Reddy, Y. N. V., & Borlaug, B. A. (2016) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2015.12.002 · Cited by 159
Influenza Vaccination in Patients With Chronic Heart Failure
Vardeny, O., Claggett, B., Udell, J. A., Packer, M., Zile, M., Rouleau, J., Swedberg, K., Desai, A. S., Lefkowitz, M., Shi, V., et al. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.10.012 · Cited by 161
“The PARADIGM-HF (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial (10) enrolled patients with symptomatic heart failure with reduced ejection fraction and randomly allocated them to receive the angiotensin receptor neprilysin inhibitor LCZ696 (sacub…”
MethodSelf-citationMogensen, U. M., Jhund, P. S., Abraham, W. T., Desai, A. S., Dickstein, K., Packer, M., Rouleau, J. L., Solomon, S. D., Swedberg, K., Zile, M. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.027 · Cited by 159
“We are not aware of any robust prior analysis of the risk associated with these 2 different types of AF in chronic HFrEF.”
BackgroundInfluentialSelf-citationSchmieder, R. E., Wagner, F., Mayr, M., Delles, C., Ott, C., Keicher, C., Hrabak-Paar, M., Heye, T., Aichner, S., Khder, Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx525 · Cited by 159
Packer, M., Claggett, B., Lefkowitz, M. P., McMurray, J. J. V., Rouleau, J. L., Solomon, S. D., & Zile, M. R. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30100-1 · Cited by 160
Self-citationPacker, M., & McMurray, J. J. V. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2149 · Cited by 160
Self-citationCanepa, M., Fonseca, C., Chioncel, O., Laroche, C., Crespo-Leiro, M. G., Coats, A. J. S., Mebazaa, A., Piepoli, M. F., Tavazzi, L., Maggioni, A. P., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.02.001 · Cited by 158
Home-Delivered Meals Postdischarge From Heart Failure Hospitalization: The GOURMET-HF Pilot Study
Hummel, S. L., Karmally, W., Gillespie, B. W., Helmke, S., Teruya, S., Wells, J., Trumble, E., Jimenez, O., Marolt, C., Wessler, J. D., et al. (2018) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004886 · Cited by 158
The Role of Cardioprotection in Cancer Therapy Cardiotoxicity
Omland, T., Heck, S. L., & Gulati, G. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.01.101 · Cited by 200
“The use of combined angiotensin receptor and neprilysin inhibition with sacubitril-valsartan provides more complete neurohormonal inhibition and was associated with reduced mortality and morbidity compared with standard treatment in patients with heart failure with reduced ejection fraction.(30) The preventive cardiop…”
MethodJCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 158
Gaziano, T. A., Fonarow, G. C., Claggett, B., Chan, W. W., Deschaseaux-Voinet, C., Turner, S. J., Rouleau, J. L., Zile, M. R., McMurray, J. J. V., & Solomon, S. D. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1747 · Cited by 157
Self-citationReddy, Y. N. V., Borlaug, B. A., & Gersh, B. J. (2022) · Circulation · doi:10.1161/circulationaha.122.057444 · Cited by 185
Braunwald, E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.033 · Cited by 163
“A perspective in the same issue of the New England Journal of Medicine stated, “We may be entering a new era of treatment for heart failure with reduced ejection fraction” (8), strong words indeed by 2 editors of this journal.”
BackgroundMethodInfluentialSolomon, S. D., Rizkala, A. R., Lefkowitz, M. P., Shi, V. C., Gong, J., Anavekar, N. S., Anker, S. D., Arango, J. L., Arenas, J., Atar, D., et al. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.004962 · Cited by 176
Self-citationMullens, W., Auricchio, A., Martens, P., Witte, K., Cowie, M. R., Delgado, V., Dickstein, K., Linde, C., Vernooy, K., Leyva, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2046 · Cited by 155
The Real-World Evidence of Heart Failure: Findings from 41 413 Patients of the ARNO Database
Maggioni, A. P., Orso, F., Calabria, S., Rossi, E., Cinconze, E., Baldasseroni, S., & Martini, N. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.471 · Cited by 175
Martens, P., Nuyens, D., Rivero‐Ayerza, M., Herendael, H. V., Vercammen, J., Ceyssens, W., Luwel, E., Dupont, M., & Müllens, W. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01440-y · Cited by 175
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Genetics and genomics of dilated cardiomyopathy and systolic heart failure
Tayal, U., Prasad, S., & Cook, S. A. (2017) · Genome Medicine · doi:10.1186/s13073-017-0410-8 · Cited by 155
“Novel heart failure therapies beyond devices have recently emerged, but it is too soon to be able to evaluate their long-term prognostic benefit [11], and whether current therapies can be tailored to an individual patient has yet to be explored in detail [12].”
BackgroundRecent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
Kandaswamy, E., & Zuo, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020424 · Cited by 180
“This drug has proven to be more effective in the treatment of heart failure than traditional Angiotensin-converting enzyme (ACE) inhibitors [136].”
BackgroundDimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · BMJ · doi:10.1136/bmj.m115 · Cited by 149
Lim, S. L., Lam, C. S. P., Segers, V. F. M., Brutsaert, D. L., & De Keulenaer, G. W. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv132 · Cited by 152
“This trial has recently been completed and published; LCZ 696 resulted in a 16% reduction in allcause mortality, 20% reduction in cardiovascular mortality and 21% reduction in HF hospitalizations among chronic HFREF patients.(97) Although augmentation of the NP pathway by LCZ 696 may be expected to boost endothelial f…”
MethodFerrari, G. M. D., Stolen, C., Tuinenburg, A. E., Wright, D. J., Brugada, J., Butter, C., Klein, H., Neužil, P., Botman, C. J., Castel, M., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.036 · Cited by 153
Self-citationNougue, H., Pezel, T., Picard, F., Sadoune, M., Arrigo, M., Beauvais, F., Launay, J., Solal, A. C., Vodovar, N., & Logeart, D. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1342 · Cited by 157
Novel RAAS agonists and antagonists: clinical applications and controversies
Romero, C. A., Orias, M., & Weir, M. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.6 · Cited by 147
“78, 79 Blood pressure was signifi cantly lower in the LCZ969 group than in the enalapril group.”
Dewan, P., Jackson, A. M., Jhund, P. S., Shen, L., Ferreira, J. P., Petrie, M. C., Abraham, W. T., Desai, A. S., Dickstein, K., Køber, L., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1832 · Cited by 161
Self-citationKing, J. B., Shah, R. U., Bress, A. P., Nelson, R. E., & Bellows, B. K. (2016) · JACC Heart Failure · doi:10.1016/j.jchf.2016.02.007 · Cited by 156
Long-term neprilysin inhibition — implications for ARNIs
Campbell, D. J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.200 · Cited by 161
Burke, R. M., Lighthouse, J. K., Mickelsen, D. M., & Small, E. M. (2019) · Circulation Heart Failure · doi:10.1161/circheartfailure.118.005565 · Cited by 159
Docherty, K. F., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.06.020 · Cited by 182
“In PARADIGM-HF, consistent benefits of sacubitril/valsartan over enalapril were observed across a range of prespecified and other subgroups, including race and geographic region (with patients enrolled in 47 countries on 6 continents) (1, 17).”
BackgroundMethodSelf-citationMüllens, W., Martens, P., Testani, J. M., Tang, W. H. W., Skouri, H. N., Verbrugge, F. H., Fudim, M., Iacoviello, M., Franke, J., Flammer, A. J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2471 · Cited by 164
Xia, Y., Chen, Z., Chen, A., Fu, M., Dong, Z., Hu, K., Yang, X., Zou, Y., Sun, A., Qian, J., et al. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.06.003 · Cited by 148
Outcomes and Effect of Treatment According to Etiology in HFrEF
Balmforth, C., Simpson, J., Shen, L., Jhund, P. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K. B., et al. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2019.02.015 · Cited by 153
Self-citationEffect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan
Solomon, S. D., Jhund, P. S., Claggett, B. L., Dewan, P., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., Sabatine, M. S., Inzucchi, S. E., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.04.008 · Cited by 170
Self-citationFrailty and heart failure: State‐of‐the‐art review
Talha, K. M., Pandey, A., Fudim, M., Butler, J., Anker, S. D., & Khan, M. S. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13306 · Cited by 181
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Self-citationButrous, H., & Hummel, S. L. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.05.005 · Cited by 144
Metadata
- Authors
- McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., & Zile, M. R.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- Montreal Heart Institute (CA)
- Imperial College London (GB)
- Medical University of South Carolina (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-09-11
- Volume
- 371
- Issue
- 11
- Pages
- 993-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2113698123
- Cited by
- 6,957
- References
- 30
- Citations by year
- 2026: 432 · 2025: 599 · 2024: 634 · 2023: 711 · 2022: 725 · 2021: 758 · 2020: 750 · 2019: 613 · 2018: 482 · 2017: 484 · 2016: 411 · 2015: 296 · 2014: 41
- FWCI
- 281.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Keele Research Repository (Keele University) (submittedVersion, cc-by)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- angiotensin receptor-neprilysin inhibition, sacubitril/valsartan, enalapril, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, heart failure symptoms, hypotension, angiotensin II receptor blockade, ACE inhibitors, renin-angiotensin system, heart failure prognosis, heart failure with preserved ejection fraction
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Enalapril, Female, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Tetrazoles, Neprilysin, Kaplan-Meier Estimate, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.